SCLC

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 21/06/2022)

Non-metastatic stage
KEYLINK-013 (MSD)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Metastatic stage

1st line

Currently no open trials

2nd line
Currently no open trials

3rd line
Currently no open trials